Stockscreener 앱 받기
19.49
5.87%
1.08
시장 영업 전:
19.47
-0.02
-0.10%
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals stock hits 52-week high at 19.19 USD - Investing.com
Amylyx Pharmaceuticals stock hits 52-week high at 19.19 USD By Investing.com - Investing.com Canada
Amylyx Pharmaceuticals Inc (AMLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Institutional Confidence - TradingKey
TradingKey - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Amylyx Pharmaceuticals Inc (AMLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AMLX|Amylyx Pharmaceuticals Inc|Price:18.410|Chg%:+0.820 - TradingKey
Amylyx Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals Inc (AMLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Chief Legal Officer & General Counsel Gina Mazzariello Sold A Bunch Of Shares In Amylyx Pharmaceuticals - 富途牛牛
Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $24 - Moomoo
Mizuho raises Amylyx stock price target to $24 ahead of trial data By Investing.com - Investing.com South Africa
Mizuho raises Amylyx stock price target to $24 ahead of trial data - Investing.com Nigeria
Mizuho Raises Price Target on Amylyx Pharmaceuticals to $24 From $21, Keeps Outperform Rating - marketscreener.com
Lobbying Update: $40,000 of AMYLYX PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Trade Alert: Chief Legal Officer & General Counsel Of Amylyx Pharmaceuticals Gina Mazzariello Has Sold Stock - Sahm
Amylyx Pharmaceuticals (AMLX) Holds Steady Near $17.30 Amid Modest Downside – Key Levels in FocusETF Inflow Streak - dars.gov.et
Insider Sell: Gina Mazzariello Sells 30,000 Shares of Amylyx Pha - GuruFocus
Amylyx Pharmaceuticals (AMLX) CLO sells 30,000 shares under 10b5-1 plan - Stock Titan
Amylyx Pharmaceuticals (AMLX) M&A Announcement Summary - Quartr
Amylyx Pharmaceuticals (AMLX) Proxy filing Summary - Quartr
Form 144 Amylyx Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria
[144] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - aol.com
Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary - Quartr
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight - Yahoo Finance
AMLXAmylyx Pharmaceuticals Inc Latest SEC Filings - Finviz
Analysts Are Bullish on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Guardian Pharmacy Services, Inc. Class A (GRDN) - The Globe and Mail
Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Are In A Position To Invest In Growth - Moomoo
Amylyx Pharmaceuticals (AMLX) Edges Higher Amid Cautious Trading at $17.99Tick Index - DonanımHaber
Amylyx Pharmaceuticals Gains Attention as LUCIDITY Trial Results LoomEarnings Power Value - dars.gov.et
Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? - Insider Monkey
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell 3000E Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark - marketscreener.com
Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gew - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Amylyx advancing ALS treatment in trial after early safety data is positive - ALS News Today
Enterprise value to revenue forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Price to sales forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Enterprise value to EBITDA forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView
Guggenheim Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Amylyx Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMLX) - TradingView
AMLX Forecast — Price Target — Prediction for 2027 - TradingView
Amylyx Pharmaceuticals stock hits 52-week high at $18.65 By Investing.com - Investing.com South Africa
AMLX Maintained by Guggenheim -- Price Target Raised to $40 - GuruFocus
Guggenheim raises Amylyx stock price target on PBH drug outlook By Investing.com - Investing.com South Africa
Guggenheim raises Amylyx stock price target on PBH drug outlook - Investing.com UK
Amylyx Pharmaceuticals stock hits 52-week high at $18.65 - Investing.com
0.30%
2.01%
자본화:
|
볼륨(24시간):